Sharemaestro Newsreel

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?

Key Points Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report. Wall Street is still bullish on the shares.10 stocks we like better than Ionis Pharmaceuticals › Shares of Ionis Pharmaceuticals(NASDAQ: IONS) …

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating

Bernstein has increased its price target for Regeneron Pharmaceuticals (REGN) to $756 from $753, while maintaining a "Market Perform" rating on the stock. This adjustment reflects a modest change in the analyst's valuation, indicating a continued neutral stance on the company's stock performance. The …

Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals

Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A

Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research

Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries

For Immediate Release Chicago, IL – August 14, 2026 – Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different …

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $35.57. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.11 EPS against an anticipated $0.06 and $129.86 million in revenue versus $118.85 …

Sei Investments Co. Buys Shares of 99,627 MeiraGTx Holdings PLC $MGTX

Nektar: Q2 Earnings Snapshot

The article provides a snapshot of Nektar's Q2 earnings. No specific financial details are available in the provided content, as the main article text was not included.

Stock index futures largely flat after S&P 500 closes at record high

[Wall Street New York stock exchange stock market] alexsl Stock index futures were muted on Friday after the S&P 500 closed at a record high in the previous session. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.12%, S&P 500 futures (SPX [https://seekingalpha.com/symbol/SPX]) +0.02%, and Nasdaq futures (US100:IND) …

Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX

Dimensional Fund Advisors LP significantly increased its stake in Bicara Therapeutics Inc. by 166.9% in the first quarter, now holding 109,261 shares valued at $2.17 million. Several other institutional investors also raised their positions, while insider sales have occurred. Bicara Therapeutics maintains a "Moderate …

Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT

Dimensional Fund Advisors LP significantly reduced its stake in Summit Therapeutics PLC by 76.5% in the first quarter, selling over 288,000 shares. Despite this, Summit Therapeutics has seen strong insider buying, with executives acquiring 7.87 million shares worth approximately $103.6 million in the past …

Dimensional Fund Advisors LP Sells 12,867 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Dimensional Fund Advisors LP reduced its stake in Rhythm Pharmaceuticals, Inc. by 40.2% in the first quarter, selling 12,867 shares and retaining 19,151 shares valued at approximately $1.67 million. Despite the sale, Rhythm Pharmaceuticals reported strong quarterly revenue growth of 46.9% year-over-year and beat …

How Investors Are Reacting To Rhythm Pharmaceuticals (RYTM) UK Orphan Expansion For IMCIVREE In Hypothalamic Obesity

Rhythm Pharmaceuticals received expanded UK MHRA authorization and orphan drug designation for IMCIVREE to treat hypothalamic obesity, broadening its market in the UK. While this strengthens the rare-disease thesis for the drug, the company continues to operate at a significant loss, underscoring ongoing funding …

Assenagon Asset Management S.A. Increases Stake in Fortrea Holdings Inc. $FTRE

Assenagon Asset Management S.A. significantly increased its stake in Fortrea Holdings Inc. by 90.7% in Q2 2026, now owning 173,129 shares valued at $3.0 million. This comes as Fortrea reported strong quarterly results, beating EPS and revenue estimates, while analysts maintain a "Hold" rating …

ADMA|ADMA Biologics Inc|Price:9.410|Chg%:-0.370

This article provides a detailed overview of ADMA Biologics Inc. (ADMA) stock, including its current price, market performance, key financial figures, and analyst ratings. It also offers technical analysis, company profile, ownership breakdown, and related instruments in the pharmaceutical sector.

Bank of America Corp DE Decreases Position in Edgewise Therapeutics, Inc. $EWTX

6 Green Days In A Row: AbCellera Biologics Stock Is Up 85%

AbCellera Biologics (ABCL) stock has surged 85% over six consecutive trading days, reaching a new 52-week high and adding $1.5 billion to its market value. While its revenue growth is strong at 101.3% over the last twelve months, the company faces profitability challenges with …

Ultragenyx Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $52, Implies 97% Upside

Ultragenyx Pharmaceutical Inc.'s average 12-month price target has been slightly reduced to $52 from $52.84 by 18 analysts. This new target implies a potential upside of approximately 97% based on the August 13th closing price. The consensus analyst rating remains a "Buy" from 19 …

Ultragenyx awaits two FDA decisions that could boost its stock to $32 from $27.

Ultragenyx Pharmaceutical is awaiting two crucial FDA decisions that could significantly impact its stock price, potentially raising it from $27 to $32 per share. The decisions involve gene therapy DTX401 for glycogen storage disease type Ia, with an 80% approval chance, and UX111, with …

Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside

Arcus Biosciences, Inc. (RCUS) has seen its average 12-month price target raised from $38.33 to $38.82 by 11 analysts, with forecasts ranging from $23 to $47 per share. This new target implies a potential upside of approximately 35% from its August 13 closing price. …

How Investors May Respond To Immunocore (IMCR) Turning First-Half Profit Amid Recent Share Price Pullback

Immunocore Holdings plc (IMCR) reported a significant improvement in its financial performance, achieving a first-half 2026 net income of US$12.16 million, up from a net loss of US$5.28 million the previous year, with revenues also increasing. This shift to profitability strengthens the investment case, …

Ultragenyx Stock Looks Undervalued Ahead Of Two FDA Decisions (NASDAQ:RARE)

Ultragenyx Pharmaceutical (RARE) is considered undervalued with a "soft Buy" rating and a probability-weighted fair value of approximately $32 per share, against its current price near $27. The company is anticipating two crucial FDA decisions soon: one for DTX401 on August 23rd and another …

TG Therapeutics (TGTX) Raised Revenue Guidance After Q2, Is It Still Below Fair Value?

TG Therapeutics (TGTX) recently reported its Q2 2026 results, showing higher revenue, lower net income, and raised full-year revenue guidance to about US$950 million. Despite a recent 13% drop, the stock is up 64% year-to-date and is considered modestly undervalued at $47.94 against a …

Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why

Summit Therapeutics (SMMT) Expands Ivonescimab Reach As Investors Ask If The Story Is Priced In

Cibus Inc (CBUS) (Q2 2026) Earnings Call Highlights: Strategic P

ATAI Beckley earnings beat by $0.03, revenue topped estimates

Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?

Despite a recent 44.2% surge in Moderna's stock price, StockStory advises against investing in the company due to declining revenue and EPS over the last five years, and a negative free cash flow margin. The analysis suggests Moderna is a low-quality business, with the …

Renaissance Technologies (CORT) discloses 4.90% beneficial stake in Corcept Therapeutics

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 4.90% in Corcept Therapeutics Inc., amounting to 5,261,628 shares of common stock. This Schedule 13G/A filing indicates that Renaissance Technologies holds sole voting and dispositive power over these shares. Certain …

MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Investor Relations - Stefanie Perna-NacarPresident and Chief Executive Officer - Jennifer BuellHead of Development - Terese HammondPrincipal Financial Officer - Melissa Orilall TAKEAWAYS Cash and Cash Equivalents -- …

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

Earnings Call Insights: Nektar Therapeutics (NKTR) Q2 2026 MANAGEMENT VIEW * “In July, we achieved yet another important milestone in Nektar with the initiation of the global ZENITH AD program, Phase III AD program for rezpegaldesleukin” (CEO, President & Director Howard W. Robin). “With …

Parabilis Medicines (PBLS) Earnings Date and Reports 2026

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

Levi & Korsinsky has announced an investigation into Ardelyx (ARDX) following a significant 17.86% stock drop on August 7, 2026. This decline occurred after the company reported second-quarter 2026 product revenue and earnings per share that were below consensus estimates, and subsequently lowered its …

Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position

Farallon Capital Management and its affiliated funds have disclosed a beneficial ownership of 10,282,210 shares of Beam Therapeutics (BEAM) common stock, representing 9.99% of the outstanding class. This position includes directly held shares and common stock purchase warrants, with exercisability capped at 9.99% due …